-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
1/38
Long-term effect of antiviral therapy on disease course after
decompensation in patients with hepatitis B virus-related
cirrhosis
Jeong Won Jang1,*, Jong Young Choi
*1,*
,†, Young Seok Kim
2,*, Hyun Young Woo
3,*, Sung
Kyu Choi4,
*, Chang Hyeong Lee5,
*, Tae Yeob Kim6,
*, Joo Hyun Sohn6,
*, Won Young
Tak 7,*, Kwang-Hyub Han
8,*
Departments of1 Internal Medicine,
1The Catholic University of Korea, College of Medicine,
2Soonchunhyang University College of Medicine,
3 Pusan National University Hospital,
4
Chonnam National University Medical School,
5
School of Medicine, Catholic University of Daegu,
6 Hanyang University Guri Hospital,
7 Kyungpook National University Hospital,
8Yonsei
University College of Medicine, * Liver Cirrhosis Clinical Research Center (LCCRC)
Running title: anti-HBV therapy for decompensated LC
E-mail address of the authors:
J W J d @ h li k J Y Ch i j h i@ h li k Y S k
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
2/38
Jang Page 2
CHB = chronic hepatitis B, CI = confidence intervals, HBeAg = hepatitis B e antigen, HBsAg =
hepatitis B surface antigen, HR = hazard ratios, PCR = polymerase chain reaction, IQR =
interquartile range.
This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry
of Health and Welfare, Republic of Korea (HI10C2020). The statistical consultation was
supported by Catholic Research Coordinating Center of the Korea Health 21 R&D Project
(A070001), Ministry of Health & Welfare, Republic of Korea.
Abstract word count: 274
Text word count including references: 5,111
Corresponding author:
Jong Young Choi, M.D.
Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of
Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 137-701,
Republic of Korea
E-mail: [email protected]
Telephone: +82-2-2258-2075, Fax: +82-2-3481-4025.
Page 2 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
3/38
Jang Page 3
ABSTRACT
The effect of viral suppression on long-term disease outcome after decompensation in patients
with hepatitis B virus (HBV)-related cirrhosis has not been established. The aim of this study
was to determine the long-term effect of antiviral therapy in patients with HBV-related
decompensated cirrhosis. This was a multicenter, prospective, inception cohort study of 707
patients who presented with first-onset decompensated complications, including 284 untreated patients and 423 antiviral-treated patients (58 previously treated, 253 with early treatment, and
112 with delayed treatment). The primary endpoint was 5-year liver transplantation (LT)-free
survival. Secondary endpoints included virologic/serologic response and improvement in liver
function. Despite baseline high HBV activity and worse liver function, antiviral-treated patients
had significantly better transplant-free survival than untreated patients (5-year survival rates of
59.7% vs. 46.0%, respectively), with more apparent benefits from antivirals in Child-Turcotte-
Pugh class B/C and high-viremia groups. The 5-year cumulative rate of virologic response and
HBeAg seroconversion in antiviral-treated patients was 14.2% and 49.1%, respectively. A
significant improvement in liver function was observed in treated versus untreated patients, with
33.9% of treated patients delisted for LT. Patients with early treatment had better clinical
outcomes than those with delayed treatment. Survival was dependent on antiviral response, being
significantly better in responders than in non responders or untreated cases The initial benefit of
Page 3 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
4/38
Jang Page 4
INTRODUCTION
An estimated 350 million individuals are chronically infected with hepatitis B virus
(HBV) worldwide.1 The annual incidence of cirrhosis among chronic HBV carriers was reported
to be approximately 2.1%−6.0%.2 After advancement to cirrhosis, liver disease may continue to
progress and decompensated complications can occur, especially in those with active HBV
replication. Hepatic decompensation among chronic HBV carriers is associated with highmortality and has a reported 5-year survival rate of 14%−35%, which is significantly lower than
the rate of 80%−85% among those with compensated cirrhosis.1-4
A substantial proportion of
cirrhotic patients still have active HBV replication as evidenced by positive hepatitis B e antigen
(HBeAg) or high HBV DNA levels,5 which are the strongest factors for disease progression.
6,7
Although understanding the natural history of HBV-related diseases may help to optimizethe care of chronic HBV carriers, information on the course of illness after the onset of
decompensation is too scanty or at best inconclusive because of the tremendous heterogeneity in
patient inclusion criteria across studies. Clinical studies to date have revealed that oral antivirals
are generally safe and effective in HBV suppression, with an improvement in liver disease in
patients presenting with HBV-related decompensation.2,8
Recent studies also showed that
profound viral suppression with newer, more potent antivirals shows short-term efficacy as
9 12
Page 4 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
5/38
Jang Page 5
PATIENTS and METHODS
Study population
This multicenter, prospective, observational, inception cohort study was conducted as
part of a study project of the Liver Cirrhosis Clinical Research Center (LCCRC) in Korea.14
Between 2005 and 2012, patients at seven Korean referral centers who met the following criteria
were entered into the study: age ≥18 years; hepatitis B surface antigen (HBsAg) carrier for ≥6
months; pathologic or clinical evidence of cirrhosis including nodularity/splenomegaly on liver
imaging and/or thrombocytopenia; presentation with the first episode of liver decompensation
defined as the occurrence of complications, such as ascites, variceal bleeding, encephalopathy,
spontaneous bacterial peritonitis (SBP), or hepatorenal syndrome. Patients with hepatocellular
carcinoma (HCC) at baseline, a history of other malignancy, and any other form of liver disease
including hepatitis C virus, serious alcoholic disease (consumption >20 grams/day), or
autoimmune hepatitis were excluded. This study (KC10RIMI0483) was approved by the local
Ethics Committees in accordance with the 1975 Declaration of Helsinki. Each patient provided
informed consent.
Assessments and follow-up
Baseline and on-study laboratory assessments included routine hematologic tests,
Page 5 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
6/38
Jang Page 6
For all patients, complications were appropriately managed according to current
guidelines in all centers.16,17
A low-salt diet and diuretics were prescribed for patients with
ascites. Patients with variceal bleeding received endoscopic band ligation/sclerotherapy or
transjugular intrahepatic portosystemic shunt, and were discharged with β-blocker secondary
prophylaxis unless contraindications were documented. Antibiotic therapy was initiated
appropriately for bacterial infection including SBP. Prophylactic antibiotics were administered
for patients with prior SBP and variceal bleeding. LT allocation was based on the Korean
Network for Organ Sharing criteria: Status 1, intensive care unit-bound fulminant liver failure
with expected survival
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
7/38
Jang Page 7
criteria, antiviral therapy was delayed until follow-up ALT/HBV DNA tests met the strict criteria
due to the high costs of antivirals in Korea, unless the patient was willing to receive antivirals
without reimbursement. Early treatment was defined as antiviral treatment initiated within 3
months of decompensation and delayed treatment if treatment was initiated after 3 months of
decompensation. In Korea, lamivudine was the only first-line agent until 2007, entecavir and
clevudine have been available since 2007, and telbivudine since 2010. Adefovir was approved
only as rescue therapy for lamivudine resistance and given as monotherapy or in combination
with continued lamivudine, depending on the patient’s liver function.
Statistical analysis
Data were expressed as the mean ± standard deviation or median (range). Categorical
variables were compared with the Chi-square test or Fisher’s exact test, means were analyzed by
the Student’s t-test and medians by the Wilcoxon rank-sum test.
Survival time was calculated as the time interval from the date of first-episode
decompensation to LT, death, or the end of follow-up. LT-free survival curves were constructed
using the Kaplan-Meier method, and differences were assessed by log-rank test. Bonferroni
correction was used for multiple comparisons (LT-free survival according to response). The
cumulative probability of HBeAg seroconversion and HCC development was determined for the
groups, with death and loss to follow-up being considered as competing risks. Continuous
Page 7 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
8/38
Jang Page 8
We were able to match 127 patients with antiviral treatment to 127 patients without treatment.
Stratified Cox regression with patients matched on propensity score was used to estimate the
treatment effect on survival. A two-sided P value
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
9/38
Jang Page 9
(14.4%) were not eligible for assessment of response due to early death, LT, or loss to follow-up
after treatment initiation. The rate of virologic response in the whole antiviral-treated group was
41.4% and 14.2% at 12 and 60 months after study inclusion, respectively. Of the 117 evaluable
non-responders, 19 eventually switched to adefovir and 17 to entecavir (1.0 mg), 50 had adefovir
add-on therapy, and 31 had no change in antivirals at further follow-up. The most common
resistance pattern observed in these patients was rtL180M + rtM204I/V (79.4%; Supplemental
table 1).
Normalization of ALT at 12 months was achieved in 63.7% (170/267) of antiviral-treated
patients with a baseline ALT above the upper limit of normal; the remainder showed no ALT
normalization (57), or were lost to follow-up (8) or LT/death (32). Overall, HBeAg
seroconversion was achieved in 81 (27.3%) of 297 HBeAg-positive patients. The probability of
HBeAg seroconversion was 13.4%, 34.7%, and 49.1% at 12, 36, and 60 months for the whole
antiviral-treated group, whereas the corresponding probability in the untreated group was 10.9%,
15.7%, and 35.1%, respectively; the rate of HBeAg seroconversion was not different between the
two groups ( P =0.2021; Figure 2A). However, when treatment time was taken into account, the
early treatment group showed a significantly higher rate of HBeAg seroconversion than the
untreated group, with a corresponding rate of 17.8%, 40.8%, and 57.4%, respectively ( P =0.0155;
Figure 2C), whereas the previous or delayed treatment groups did not show an increase in
HBeAg seroconversion ( P >0.05; Supplemental figure 1).
Page 9 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
10/38
Jang Page 10
untreated patients, respectively, remained in CTP class A ( P
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
11/38
Jang Page 11
and 73.0% in the responder group; 76.1%, 58.2%, and 42.7% in the non-responder group; and
73.2%, 55.8%, and 46.0% in the control group, respectively (Figure 2E).
Prognostic factors
To evaluate factors that affected survival, the clinical variables listed in Table 2 were
included in the analysis. Cox proportional hazard regression analysis showed that sex, age,
decompensated complications, CTP class, MELD score, and antiviral therapy were
independently predictive of LT-free survival. When analyzed within the antiviral-treated group,
age, MELD scores and response to antiviral therapy remained independently predictive of
survival (Table 3). The adjusted survival was significantly better in antiviral-treated patients than
in untreated patients (hazard ratio [HR] 1.68, 95% confidence interval [CI] 1.32−2.12, P
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
12/38
Jang Page 12
first few years, but this difference was negated during continued follow-up and survival was
comparable to that of untreated controls after 5 years ( P =0.3664).
Finally, we analyzed the incidence of HCC in this propensity score-matched cohort.
Overall, 56 patients of the cohort developed HCC; 46 developed HCC after 1 year, while 10
developed HCC within 1 year. These 10 were excluded from the analysis, because they were
presumed to have pre-existing HCC that was not detected at baseline. The cumulative incidence
of HCC at 5 years was 35.1% and 29.4% in the antiviral-treated and untreated groups,
respectively ( P =0.6452). When the whole cohort was taken into account, the corresponding
incidence was 32.3% and 27.2%, respectively ( P =0.3033). For both cohort analyses, there was
no difference in the incidence of HCC between patients with and without treatment.
DISCUSSION
The major strength of our study is that it represents the largest prospective study ever
reported and one of the longest followed cohort studies of HBV-related decompensated cirrhosis.
Moreover, the current study enlisted subjects at a uniform point in the course of liver disease
(first onset decompensated complications) under strict inclusion criteria The inclusion of an
Page 12 of 39Hepatology
P 13 f 39 H t l
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
13/38
Jang Page 13
CTP or MELD scores at 5 years. In contrast to earlier studies in this setting with follow-up
limited to 1−2 years,9-12
our study presented long-term results, indicating that the improvement in
liver function by treatment can be maintained for up to 5 years, thus delaying or avoiding the
need for LT in approximately 60% of patients who were otherwise considered for LT.
Specifically, 33.9% of antiviral-treated patients were eventually delisted for LT within 1 year.
Lastly, antiviral therapy significantly prolonged survival, which was better in patients with than
without response or untreated patients. The overall benefits of antiviral therapy appear even more
solid, given that the treated cohort had unfavorable baseline characteristics, including more
patients with higher HBV activity and worse liver biochemical profiles, compared with the
untreated controls. This underscores the fundamental need for antiviral administration in these
patients.
Although regional practice guidelines recommend early antiviral therapy for HBV-
related decompensated cirrhosis,1,18,19 it is not certain if initiating treatment earlier would
improve the rate of response and translate into a meaningful long-term outcome. Importantly, our
findings addressed this issue and confirmed the superior effects of early antiviral intervention in
these patients. Efficacy measures were significantly better in patients with early initiation of
antivirals upon presentation of decompensation than in those with delayed therapy. Intriguingly,
our study is the first to demonstrate a higher rate of HBeAg seroconversion in patients who
received early antiviral treatment compared with untreated controls, which has not been observed
Page 13 of 39 Hepatology
Page 14 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
14/38
Jang Page 14
patients with compensated diseases to the setting of decompensated cirrhosis,23
demonstrating
that the antiviral effect remains valid even after developing decompensation. Considering that
maintaining potent suppression of HBV led to better long-term results and that HBeAg, HBV
DNA, and aminotransferase levels had little impact on the outcomes, our findings again support
the current guidelines that recommend tenofovir or entecavir as a preferred first-line choice for
patients with liver cirrhosis, even when HBV DNA and aminotransferase levels are only
modest.1,18,19
Despite these long-term beneficial effects of treatment, not all treated patients survived
an episode of decompensation, especially during the early period of therapy. In our results, 13.4%
(34/253) of patients, mostly those with severe hepatic dysfunction, died within 6 months,
compatible with previous observations.8 This implies that, because it takes several months for
liver function to recover after initiating antivirals,5,13
any patient with severe decompensation
should be considered for LT even if antiviral therapy is initiated. Recently, anti-HBV therapy
was shown to reduce the risk of HCC in patients with compensated cirrhosis.23-25
However, we
found no protective effect in patients with decompensated cirrhosis. This might be due to the
relatively short survival of these patients, but another possible explanation is that genetic
alterations in cirrhotic nodules may have pre-existed before initiation of antivirals. Thus, patients
presenting with decompensation should be started early with antiviral therapy and monitored
closely with regular HCC surveillance while under consideration for LT.
Page 14 of 39Hepatology
Page 15 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
15/38
Jang Page 15
observed in untreated cases. Indeed, there were only five deaths other than early mortality in
these groups with early treatment (data not shown). Thus, the beneficial effect of antivirals in
these low-risk groups will likely become obvious with more extended follow-up. It may also be
argued that the treatment group included more patients with acute decompensation secondary to
hepatitis flares, who were likely to have a better prognosis2 and thus contributed to the increased
survival compared to untreated controls. However, exclusion of patients with hepatitis flares
from the analysis did not significantly change the results.
It would not be ethically justifiable to include untreated controls in studies of cirrhosis.
However, reimbursement for anti-HBV agents strictly limited to specified indications in Korea
provided us a unique and valuable opportunity to explore the natural history following
decompensation and the long-term effects of antiviral therapy with the inclusion of contemporary
untreated controls. Our study has additional limitations. Changes in hepatic function were
assessed in surviving patients with tests at index time points. Such a select picture may lead to
the potential for overestimating treatment effects by excluding those with missing data. The cut-
off value defining virologic response (400 IU/mL) was arbitrary and insensitive because non-
PCR assays were used for HBV DNA testing during the first few years of the study initiation.
However, by definition, most of our patients achieving response were entecavir-treated or
successfully rescued patients who continued to have undetectable HBV DNA levels even usingPCR methods during extended follow-up. It is possible that a subset of critically ill patients who
Page 15 of 39 Hepatology
Page 16 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
16/38
Jang Page 16
In conclusion, anti-HBV therapy significantly modifies the natural history of
decompensated cirrhosis, improving liver function and increasing survival. Early intervention
with potent antivirals provides better virologic and serologic responses in these patients.
Maintained virologic response in patients under antiviral therapy leads to better long-term LT-
free survival, compared with non-responders or untreated patients. Liver function continues to
improve and is maintained for up to 5 years, delaying the need for LT especially in responders.
Thus, antiviral interventions to achieve potent and durable suppression of HBV should be
promptly initiated in patients with decompensated cirrhosis under consideration for LT.
Page 16 of 39Hepatology
Page 17 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
17/38
Jang Page 17
Acknowledgements
We thank Professor Hyeon Woo Yim and Mi Sun Park for their helpful statistical
assistance. The study protocol was approved by the Institutional Review Boards at all of the
participating hospitals (approval number KC10RIMI0483; Title of the study, “Clinical Study for
Epidemiologic, Clinical Features, Survival, and Prognosis of the Patients with Liver Cirrhosis in
Korea”). The results presented herein are part of the aforementioned study. The overall study
projects were supported by the Liver Cirrhosis Clinical Research Center (LCCRC), which has
been supervised by National Strategic Coordinating Center for Clinical Research, Ministry of
Health and Welfare, Republic of Korea (HI10C2020). Additional information on the study
projects is available at: http://www.lc-center.org.
Page 17 of 39 Hepatology
Page 18 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
18/38
Jang Page 18
REFERENCES
1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J
Hepatol 2012;57:167-185.2. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment.
Semin Liver Dis 2006;26:142-152.
3. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M.Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.
Gastroenterology 1992;103:1630-1635.
4. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al.
Occurrence of hepatocellular carcinoma and decompensation in western European patients withcirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology
1995;21:77-82.
5. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
6. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and
the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based
on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.8. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants
of early mortality in patients with decompensated chronic hepatitis B treated with antiviraltherapy. Gastroenterology 2002;123:719-727.
9. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in
treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol2010;52:176-182.
10. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al.
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients withdecompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
11 Li YF R l Gi i M Ch i H S i SK T d T L N l
Page 18 of 39Hepatology
Page 19 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
19/38
Jang Page 19
16. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV
consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol
2005;43:167-176.17. European Association for the Study of the Liver. EASL clinical practice guidelines on the
management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
J Hepatol 2010;53:397-417.18. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific
consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int
2008;2:263-283.19. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
20. Bruix J, Sherman M, American Association for the Study of Liver D. Management ofhepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
21. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virusgenotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci
2005;20:816-820.
22. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults withdecompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-689.
23. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients
with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.24. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of
hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a
systematic review. J Hepatol 2010;53:348-356.
25. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis Binfection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.
g p gy
Page 20 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
20/38
Jang Page 20
FIGURE LEGENDS
Figure 1. Flow diagram of patient enrollment. FU, follow-up; ARDS, adult respiratory distress
syndrome.
Figure 2. Cumulative rate of HBeAg seroconversion and transplant-free survival in (A-B) the
whole cohort and (C-D) early treatment group. *Adjusted for age and sex. (E) Survival according
to treatment response in the whole cohort. **Bonferroni-adjusted P value.
Figure 3. Mean changes from baseline in (A) Child-Pugh score, and (B) MELD score, at 6, 12,
36, and 60 months for the control and each treatment group. Tx, treatment. * P
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
21/38
Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
22/38
Table 2. Factors for transplant-free survival
HR, Hazard ratio; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CTP, Child-Turcotte-Pugh; MELD
Disease.
Entire cohort (n = 707) Propensity-score matched cohort (n = 254)
Univariate Multivariate Univariate Multivaria
HR (95% CI) P Adjusted HR (95% CI) P HR (95% CI) P Adjusted HR
Male sex 1.43 (1.12−1.82) 0.003 1.42 (1.10−1.83) 0.006 1.20 (0.60−2.38) 0.602
Age > 55 years 1.39 (1.12−1.73) 0.003 1.35 (1.06−1.70) 0.012 2.30 (1.20−4.42) 0.012 3.24 (1.28−
Multiple complications 1.98 (1.51−2.58) 70 IU/L 1.32 (1.06−1.65) 0.012 1.01 (0.78−1.31) 0.890 1.38 (0.75−2.54) 0.288
ALT > 40 IU/L 1.15 (0.92−1.43) 0.210 1.04 (0.58−1.87) 0.882
CTP class C 1.43 (1.28−1.60)
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
23/38
Table 3. Factors for transplant-free survival among the antiviral-treated group
HR, Hazard ratio; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CTP, Child-Turcotte-Pugh; MELD
Disease.
Entire cohort (n = 423) Propensity-score matched cohort (n = 127)
Univariate Multivariate Univariate Multivaria
HR (95% CI) P Adjusted HR (95% CI) P HR (95% CI) P Adjusted HR
Male sex 1.28 (0.93−1.77) 0.126 1.28 (0.70−2.35) 0.414
Age > 55 years 1.60 (1.18−2.17) 0.002 1.58 (1.16−2.15) 0.003 2.14 (1.11−4.14) 0.023 1.93 (0.99−
Multiple complications 1.69 (1.14−2.50) 0.008 1.37 (0.91−2.05) 0.123 1.60 (0.78−3.27) 0.192
HBeAg seropositivity 1.18 (0.87−1.60) 0.278 1.21 (0.72−2.04) 0.467
High HBV activity 1.37 (0.76−2.46) 0.291 1.19 (0.61−2.30) 0.600
AST > 70 IU/L 1.14 (0.84−1.55) 0.384 1.17 (0.69−1.98) 0.543
ALT > 40 IU/L 1.04 (0.76−1.43) 0.768 1.39 (0.82−2.36) 0.211
CTP class C 1.29 (1.11−1.51) 0.001 1.08 (0.81−1.44) 0.579 1.48 (0.87−2.52) 0.140
MELD score > 15 2.31 (1.69−3.14)
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
24/38
Figure 1253x189mm (300 x 300 DPI)
Page 26 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
25/38
Figure 2AB251x148mm (300 x 300 DPI)
Page 27 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
26/38
Figure 2CD251x148mm (300 x 300 DPI)
Page 28 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
27/38
Figure 2E
200x156mm (300 x 300 DPI)
Page 29 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
28/38
Figure 3A251x149mm (300 x 300 DPI)
Page 30 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
29/38
Figure 3B
251x151mm (300 x 300 DPI)
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
30/38
Page 32 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
31/38
Figure 4B
200x156mm (300 x 300 DPI)
Page 33 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
32/38
Supplemental Table 1. Genotypic resistant profiles observed in patients with drug
resistance
Resistant profiles Patients ( n = 68)
Lamivudine-resistance mutation
rtM204I/V 10 (14.7%)
rtL180M 1 (1.5%)
rtL180M + rtM204I/V 54 (79.4%)rtL80V + rtL180M + rtM204I/V 1 (1.5%)
Adefovir-resistance mutation
rtN236T 1 (1.5%)
rtA181V/T + rtN236T 1 (1.5%)
The remaining 36 patients with drug resistance were not tested for genotypic mutation (n =30) or showed no mutation (n = 6), but all of them showed viral rebound (increase in serum
HBV DNA by > 10-fold) above nadir during therapy.
Page 34 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
33/38
Supplemental Table 2. Factors for transplant-free survival among the antiviral-treated group
HR, Hazard ratio; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MELD, Model for End-Stage Liver Disease.*MELD score: continuous variable
**Comparison between the early and delayed treatment groups
Entire cohort (n = 423) Propensity-score matched cohort (n = 127)
Univariate Multivariate Univariate Multivariate
HR (95% CI) P Adjusted HR (95% CI) P HR (95% CI) P Adjusted HR (95% CI) P
Male sex 1.28 (0.93- 1.77) 0.126 1.28 (0.70- 2.35) 0.414
Age > 55 years 1.60 (1.18- 2.17) 0.002 1.63 (1.20- 2.22) 0.002 2.14 (1.11- 4.14) 0.023 2.20 (1.12- 4.30) 0.021
Multiple complications 1.69 (1.14- 2.50) 0.008 1.10 (0.73- 1.70) 0.598 1.60 (0.78- 3.27) 0.192
HBeAg seropositivity 1.18 (0.87- 1.60) 0.278 1.21 (0.72- 2.04) 0.467
High HBV activity 1.37 (0.76- 2.46) 0.291 1.19 (0.61- 2.30) 0.600
AST > 70 IU/L 1.14 (0.84- 1.55) 0.384 1.17 (0.69- 1.98) 0.543
ALT > 40 IU/L 1.04 (0.76- 1.43) 0.768 1.39 (0.82- 2.36) 0.211
Child-Pugh class C 1.29 (1.11- 1.51) 0.001 1.05 (0.74- 1.48) 0.782 1.48 (0.87- 2.52) 0.140
MELD score (cont.)* 1.08 (1.06- 1.11)
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
34/38
SUPPLEMENTARY DATA
Supplemental figure 1. HBeAg seroconversion according to treatment groups. The
probability of HBeAg seroconversion of either group was compared with untreated patients
(No Tx) as a reference group. Previous Tx versus No Tx, P = 0.6560; Early Tx versus No Tx,
P = 0.0155; Delayed Tx versus No Tx, P = 0.7159.
Tx, treatment.
Supplemental figures 2. Liver transplantation-free survival in the (A) Child-Turcotte-Pugh
class A, (B) class B, and (C) class C groups. The cumulative survival rate was significantly
higher in antiviral-treated patients than in untreated patients among the Child-Turcotte-Pugh
class B (P = 0.0117) and class C (P < 0.0001) groups, whereas the survival rate was not
significantly different between treated and untreated patients among the class A group (P =
0.9112). Analysis was done in patients with early antiviral treatment.
Supplemental figures 3. Liver transplantation-free survival in the MELD scores (A) < 13
and (B) ³13 groups. The cumulative survival rate was significantly higher in treated than in
t t d ti t f b th th ith l MELD ( 13) (P 0 0262) d th
Page 36 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
35/38
Hepatology
This article is protected by copyright. All rights reserved.
Page 37 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
36/38
Hepatology
This article is protected by copyright. All rights reserved.
Page 38 of 39Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
37/38
Hepatology
This article is protected by copyright. All rights reserved.
Page 39 of 39 Hepatology
-
8/17/2019 2015 Hepatol Long Term Antivirals in Decomp HBV Cirrhosis
38/38
Hepatology
This article is protected by copyright. All rights reserved.